CIDIE   24052
CENTRO DE INVESTIGACION Y DESARROLLO EN INMUNOLOGIA Y ENFERMEDADES INFECCIOSAS
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
DEVELOPMENT OF AN ORAL VACCINE PLATFORM WITH SURFACE PROTEINS FROM Giardia lamblia
Autor/es:
LUCÍA RUPIL; LUCIANA AGOSTINA FASSOLA; FLORENCIA AYLIN ÑANCUFIL; MARIANELA C SERRADELL; PABLO R GARGANTINI; GUILLERMO ALBRIEU-LLINÁS
Reunión:
Jornada; XXIII Jornadas anuales de la Sociedad Argentina de Biología; 2021
Institución organizadora:
Sociedad Argentina de Biología
Resumen:
Overwhelming evidence demonstrates the benefits of immunization as one of the most successful and cost-effective healthinterventions achieved to date. Although parenteral immunization is generally effective in eliminating systemic infections, it often fails toestablish protective responses on mucosal surfaces, where most infectious agents initiate infection. Mucosal vaccines target the commonmucosal immune system and achieve a more complete protective immune response by conferring local as well as systemic immunity.Oral immunization is the most widely used form of mucosal vaccines, due to its ease of administration. But, to achieve properbioavailability oral vaccines must avoid antigen degradation by digestive proteases.We have recently developed a vaccine platform that leverages the properties of Giardia lamblia?s variant-specific surfaceproteins (VSPs) to allow oral immunization of subunit vaccines. VSPs cover the entire surface of this parasite that inhabits the uppergastrointestinal tract where digestive enzymes have their highest concentration. Since VSPs have an outstanding resistance to proteasesand to changes in pH, high immunogenicity and absence of toxicity, we engineered them to accommodate at a virus like particle (VLP),and demonstrated that they could confer protection to a viral antigen displayed on the particle. As a proof of concept, mice were orallyimmunized with VLPs containing glycoproteins of influenza virus and VSP1267. Immunized mice generated an efficient humoral andcellular, mucosal and systemic immune response that protected them from infection with the virus and from tumours expressing viralantigens. These exciting results prompted us to study the application of this platform as a potential vaccine for several other viruses.In conclusion, this novel vaccine platform provides new opportunities in the field of vaccine technology to ultimately achievemore efficient vaccines with better patient compliance.